Pharming Group (NASDAQ:PHAR) Shares Gap Down to $9.91

Pharming Group (NASDAQ:PHAR) shares gapped down prior to trading on Tuesday . The stock had previously closed at $9.91, but opened at $9.36. Pharming Group shares last traded at $9.36, with a volume of 589 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 14th.

Pharming Group Stock Down 4.3 %

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.33 and a current ratio of 4.06. The stock has a market cap of $671.09 million, a price-to-earnings ratio of -68.78 and a beta of 0.20. The firm’s 50-day simple moving average is $10.75 and its two-hundred day simple moving average is $11.37.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.08). The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. On average, sell-side analysts expect that Pharming Group will post -0.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of Pharming Group (NASDAQ:PHAR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.